Martinsried / Munich, Germany (Press Release) – MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Janssen Biotech, and Genmab, A/S for patent infringement of U.S. Patent Number 8,263,746. This patent, which is owned by MorphoSys, describes and claims anti­bodies with particular features that bind to CD38.

By its complaint, MorphoSys seeks redress for the infringing manu­fac­ture, use and sale of Janssen's and Genmab's dara­tu­mu­mab, an anti­body targeting CD38. Janssen and Genmab recently obtained FDA approval on dara­tu­mu­mab and are mar­ket­ing the prod­uct as Darzalex® in the U.S. MorphoSys con­tinues to de­vel­op MOR202, its own inves­ti­ga­tional human anti­body to CD38, for the treat­ment of cancer, in­­clud­ing multiple myeloma.

About MorphoSys:

MorphoSys devel­oped HuCAL, the most suc­cess­ful anti­body library tech­nology in the pharma­ceu­tical industry. By suc­cess­fully applying this and other patented tech­nolo­gies, MorphoSys has be­come a leader in the field of thera­peutic anti­bodies, one of the fastest-growing drug classes in human health­care.

Together with its pharma­ceu­tical partners, MorphoSys has built a thera­peutic pipe­line of more than 100 human anti­body drug can­di­dates for the treat­ment of cancer, rheumatoid arthritis, and Alzheimer's dis­ease, to name just a few. With its ongoing com­mitment to new anti­body tech­nology and drug devel­op­ment, MorphoSys is focused on making the health­care prod­ucts of tomorrow. MorphoSys is listed on the Frankfurt Stock Ex­change under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high poten­tials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.

Darzalex® is a registered trademark of Johnson & Johnson.

This communication con­tains cer­tain for­ward-looking state­ments con­cern­ing the MorphoSys group of com­pa­nies, The for­ward-looking state­ments con­tained herein rep­re­sent the judg­ment of MorphoSys as of the date of this release and in­volve­ risks and un­cer­tain­ties, Should actual con­di­tions differ from the Com­pany's assump­tions, actual results and actions may differ from those antic­i­pated, MorphoSys does not in­tend to update any of these for­ward-looking state­ments as far as the wording of the relevant press release is con­cerned.

Source: MorphoSys.